Modality
Small Molecule
MOA
WEE1i
Target
CFTR
Pathway
Hedgehog
PV
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
Oct 2017
→ May 2029
Phase 2Current
NCT07787674
1,395 pts·PV
2017-10→2025-03·Not yet recruiting
NCT07651779
1,366 pts·PV
2023-12→2029-05·Not yet recruiting
2,761 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-03-031.1y agoPh3 Readout· PV
2029-05-103.1y awayPh3 Readout· PV
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
P2/3
Not yet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-03-03 · 1.1y ago
PV
Ph3 Readout
2029-05-10 · 3.1y away
PV
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07787674 | Phase 2/3 | PV | Not yet recr... | 1395 | HbA1c |
| NCT07651779 | Phase 2/3 | PV | Not yet recr... | 1366 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |